For research use only. Not for therapeutic Use.
CBL0100（Cat No.:I024214）is an investigational small molecule designed to inhibit the activation of the mitogen-activated protein kinase (MAPK) pathway, which plays a critical role in cancer cell proliferation, survival, and metastasis. By targeting key proteins within this pathway, CBL0100 aims to disrupt the growth and spread of cancer cells, particularly in cancers with MAPK pathway dysregulation, such as melanoma. It has shown potential in preclinical studies for its antitumor activity and ability to overcome resistance to other therapies. Ongoing clinical trials are exploring its safety, efficacy, and potential as a novel cancer treatment.
| Catalog Number | I024214 |
| CAS Number | 1197996-83-0 |
| Synonyms | Curaxin 100; Curaxin100; Curaxin-100; CBL0100; CBL-0100; CBL 0100 |
| Molecular Formula | C24H26N2O2 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 11-[2-(diethylamino)ethyl]-11-azapentacyclo[10.7.0.02,10.03,7.015,19]nonadeca-1(12),2(10),3(7),8,13,15(19)-hexaene-6,16-dione |
| InChI | InChI=1S/C24H26N2O2/c1-3-25(4-2)13-14-26-19-9-5-15-17(7-11-21(15)27)23(19)24-18-8-12-22(28)16(18)6-10-20(24)26/h5-6,9-10H,3-4,7-8,11-14H2,1-2H3 |
| InChIKey | WBNDUJWRJNLCBD-UHFFFAOYSA-N |
| SMILES | CCN(CC)CCN1C2=C(C3=C(C=C2)C(=O)CC3)C4=C1C=CC5=C4CCC5=O |
